Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP8 | P22894 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 4/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2108033 | 1.00 | MMP2 (0.37) | MMP2MMP9MMP8CTSLCTSS | |
| SCHEMBL3070832 | 0.88 | MMP2 (0.37) | MMP2MMP9MMP8CTSLCTSS | |
| SCHEMBL1796260 | 0.86 | DPP4 (0.42) | DPP4LAP3ALDH1A1 | |
| SCHEMBL2184616 | 0.84 | MMP2 (0.39) | MMP2MMP9MMP8CTSLCTSS | |
| SCHEMBL28082201 | 0.84 | MMP2 (0.39) | MMP2MMP9MMP8CTSLCTSS | |
| SCHEMBL1795666 | 0.82 | SLC7A5 (0.40) | — | |
| SCHEMBL1711477 | 0.82 | ALDH1A1 (0.51) | LAP3ALDH1A1 | |
| SCHEMBL1711472 | 0.82 | ALDH1A1 (0.51) | LAP3ALDH1A1 | |
| SCHEMBL29531361 | 0.82 | ALDH1A1 (0.51) | LAP3ALDH1A1 | |
| SCHEMBL30913906 | 0.82 | ALDH1A1 (0.43) | MMP2LAP3ALDH1A1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1909846-B1 | TRIAZOLE-CONTAINING RELEASABLE LINKERS, CONJUGATES COMPRISING THE SAME AND PROCESSES FOR THEIR PREPARATION | SYNTARGA BV (NL) | 2018-12-26 | — | — | EP | disclosed |
| US-8158590-B2 | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation | SYNTARGA B.V. (NL) | 2012-04-17 | — | — | US | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
| EP-1909846-A2 | TRIAZOLE-CONTAINING RELEASABLE LINKERS, CONJUGATES THEREOF, AND METHODS OF PREPARATION | Syntarga B.V. (NL) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007018431-A2 | TRIAZOLE-CONTAINING RELEASABLE LINKERS AND CONJUGATES COMPRISING THE SAME | SYNTARGA B.V. (NL) | 2007-02-15 | — | — | WO | disclosed |
| US-20040014652-A1 | Tumor activated prodrug compounds and methods of making and using the same | DIATOS SA (FR) | 2004-01-22 | — | — | US | disclosed |
| EP-1286700-A2 | TUMOR ACTIVATED PRODRUG COMPOUNDS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001091798-A2 | TUMOR ACTIVATED PRODRUG COMPOUNDS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | MMP2 996/4885MMP9 739/4885MMP8 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.